secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001193125-22-302822
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio prices $35M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Offering of 126,815 shares at $5.52/share and pre-funded warrants to purchase 6,213,776 shares at $5.51999 each.
- Gross proceeds of ~$35M; net proceeds ~$32.5M after underwriting discounts and expenses.
- Oversubscribed offering with participation from Venrock, Adage Capital, Cormorant, and others.
- Net proceeds to fund CABA-201 preclinical and IND, and ongoing DSG3-CAART and MuSK-CAART trials.
- Closing expected December 12, 2022; Cowen and Evercore acted as joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312522302822/0001193125-22-302822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312522302822/d397326d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-302822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer